Logo image of CSLR

COMPLETE SOLARIA INC (CSLR) Stock Fundamental Analysis

NASDAQ:CSLR - Nasdaq - US20460L1044 - Common Stock - Currency: USD

1.805  -0.15 (-7.44%)

After market: 1.84 +0.04 (+1.94%)

Fundamental Rating

1

Overall CSLR gets a fundamental rating of 1 out of 10. We evaluated CSLR against 0 industry peers in the Unkown industry. CSLR has a bad profitability rating. Also its financial health evaluation is rather negative. CSLR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CSLR had negative earnings in the past year.
In the past year CSLR has reported a negative cash flow from operations.
CSLR Yearly Net Income VS EBIT VS OCF VS FCFCSLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -50M -100M -150M -200M -250M

1.2 Ratios

Industry RankSector Rank
ROA -778.67%
ROE N/A
ROIC N/A
ROA(3y)-188.81%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSLR Yearly ROA, ROE, ROICCSLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

CSLR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CSLR Yearly Profit, Operating, Gross MarginsCSLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

CSLR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSLR has more shares outstanding
Compared to 1 year ago, CSLR has a worse debt to assets ratio.
CSLR Yearly Shares OutstandingCSLR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M
CSLR Yearly Total Debt VS Total AssetsCSLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

CSLR has an Altman-Z score of -21.56. This is a bad value and indicates that CSLR is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.56
ROIC/WACCN/A
WACC7.25%
CSLR Yearly LT Debt VS Equity VS FCFCSLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

CSLR has a Current Ratio of 0.21. This is a bad value and indicates that CSLR is not financially healthy enough and could expect problems in meeting its short term obligations.
CSLR has a Quick Ratio of 0.21. This is a bad value and indicates that CSLR is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.21
Quick Ratio 0.19
CSLR Yearly Current Assets VS Current LiabilitesCSLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

CSLR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -686.30%.
CSLR shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.50%.
EPS 1Y (TTM)-686.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.9%
Revenue 1Y (TTM)41.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-89.38%

3.2 Future

The Earnings Per Share is expected to grow by 24.76% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 65.04% on average over the next years. This is a very strong growth
EPS Next Y34.43%
EPS Next 2Y27.37%
EPS Next 3Y24.01%
EPS Next 5Y24.76%
Revenue Next Year-14.39%
Revenue Next 2Y73.65%
Revenue Next 3Y57.77%
Revenue Next 5Y65.04%

3.3 Evolution

CSLR Yearly Revenue VS EstimatesCSLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 200M 400M 600M 800M
CSLR Yearly EPS VS EstimatesCSLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CSLR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CSLR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSLR Price Earnings VS Forward Price EarningsCSLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSLR Per share dataCSLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as CSLR's earnings are expected to grow with 24.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.37%
EPS Next 3Y24.01%

More info and screens

0

5. Dividend

5.1 Amount

CSLR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPLETE SOLARIA INC

NASDAQ:CSLR (4/21/2025, 8:04:08 PM)

After market: 1.84 +0.04 (+1.94%)

1.805

-0.15 (-7.44%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)04-23 2025-04-23/bmo
Earnings (Next)08-12 2025-08-12/amc
Inst OwnersN/A
Inst Owner Change2.09%
Ins OwnersN/A
Ins Owner Change0%
Market Cap35.86M
Analysts80
Price Target4.08 (126.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-240.66%
Min EPS beat(2)-363.46%
Max EPS beat(2)-117.86%
EPS beat(4)0
Avg EPS beat(4)-449.39%
Min EPS beat(4)-725.3%
Max EPS beat(4)-117.86%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.42%
Min Revenue beat(2)-58.06%
Max Revenue beat(2)-52.79%
Revenue beat(4)0
Avg Revenue beat(4)-32.81%
Min Revenue beat(4)-58.06%
Max Revenue beat(4)-9.68%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-21.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.89%
Revenue NY rev (3m)26.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.6
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.99
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS3.01
BVpS-4.63
TBVpS-4.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -778.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.24%
FCFM N/A
ROA(3y)-188.81%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -449.51%
Cap/Sales 3.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.21
Quick Ratio 0.19
Altman-Z -21.56
F-Score3
WACC7.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-686.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.9%
EPS Next Y34.43%
EPS Next 2Y27.37%
EPS Next 3Y24.01%
EPS Next 5Y24.76%
Revenue 1Y (TTM)41.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-89.38%
Revenue Next Year-14.39%
Revenue Next 2Y73.65%
Revenue Next 3Y57.77%
Revenue Next 5Y65.04%
EBIT growth 1Y-51.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.58%
EBIT Next 3Y36.36%
EBIT Next 5YN/A
FCF growth 1Y-4137.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3999.6%
OCF growth 3YN/A
OCF growth 5YN/A